In vitro activity of temafloxacin against pathogens causing sexually transmitted diseases.
The fluoroquinolones represent a new therapeutic alternative for the treatment of many sexually transmitted diseases, especially those caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, and Urea-plasma urealyticum. In vitro studies have demonstrated the 90% minimal inhibitory concentrations (MIC90s) of temafloxacin for these pathogens to be less than 0.03 micrograms/mL for N. gonorrhoeae; 0.25 micrograms/mL for C. trachomatis; 0.125-2 micrograms/mL for M. hominis; and 4 micrograms/mL for U. urealyticum. These concentrations are equal to or less than those achievable in plasma following a 400-mg temafloxacin oral dose given twice daily. Based on temafloxacin's antimicrobial activity and pharmacokinetic profile, it appears to be an excellent agent for the treatment of patients with gonococcal or nongonococcal urethritis and/or cervicitis.
Segreti
J
J
Section of Infectious Diseases, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612.
D000890:Anti-Infective Agents / Q000494:pharmacology*; D002692:Chlamydia trachomatis / Q000187:drug effects; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D009174:Mycoplasma / Q000187:drug effects; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D015363:Quinolones / Q000494:pharmacology*; D015231:Sexually Transmitted Diseases, Bacterial / Q000382:microbiology; D014210:Treponema pallidum / Q000187:drug effects; D016990:Ureaplasma urealyticum / Q000187:drug effects
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C054745:temafloxacin